Home > Rheumatology > EULAR 2020 > Psoriatic Arthritis > Secukinumab monotherapy as efficient as adalimumab

Secukinumab monotherapy as efficient as adalimumab

Main trial data from the head-to-head EXCEED trial showed that, for patients who suffer from psoriatic arthritis and who are biologic-naïve, secukinumab monotherapy does not offer greater musculoskeletal benefits than adalimumab [1].

The EXCEED trial is a phase 3b study of patients with active psoriatic arthritis and an inadequate response or intolerance to conventional disease-modifying antirheumatic drugs (DMARDs). The trial compared secukinumab and adalimumab as first-line biologic monotherapy through 52 weeks, with a musculoskeletal primary endpoint.

A total of 853 patients were randomised to secukinumab 300 mg/week at weeks 0-4 and every 4 weeks thereafter (n=426) or adalimumab 40 mg subcutaneous at baseline and then every 2 weeks until week 50 (n=427). Baseline demographics and disease characteristics were comparable between treatment-groups apart from the fact that the secukinumab group held a higher proportion of female patients as well as p...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on